CD22-Specific Antibodies for Malignant B Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments and diagnostics for CD22-expressing malignant B cells lack effective and specific antibodies that can target CD22 with high affinity and specificity, limiting therapeutic and diagnostic applications.
Innovation Solution
Development of specific antibodies that bind to CD22 with high affinity, including chimeric and humanized antibodies designed to target CD22 epitopes, which can induce apoptosis in CD22-expressing cells and are suitable for various therapeutic, diagnostic, and monitoring applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments and diagnostics are used for CD22-expressing malignant B cells, then existing therapeutic options are available, but effective and specific antibody targeting is lacking
Solution Approach 1:
The patent applies local quality by engineering antibodies with specific structural characteristics in the CDR regions to achieve high affinity and specificity for CD22. The chimeric and humanized antibody designs modify specific local regions (CDR loops) while maintaining overall antibody structure, enabling selective binding to CD22 epitopes on malignant B cells without affecting other cell types.
Solution Approach 2:
The patent employs parameter changes by systematically varying antibody sequence parameters (amino acid sequences in CDR1, CDR2, and CDR3 regions) to optimize binding affinity and specificity. Multiple antibody variants are generated with different sequence parameters to achieve the desired balance between high affinity for CD22 and minimal cross-reactivity with normal B cells.
2Measurement precision
If high affinity binding to CD22 is achieved, then therapeutic targeting is improved, but risk of off-target effects may increase
Solution Approach 1:
The patent uses local quality by precisely engineering the CDR regions to recognize specific epitopes on CD22 that are predominantly or exclusively expressed on malignant B cells. This localized specificity in the antigen-binding regions allows high affinity binding to target cells while minimizing interaction with normal cells that express lower levels or different conformations of CD22.
Solution Approach 2:
The patent applies partial action by designing antibodies that bind with high affinity to the specific CD22 epitopes present on malignant cells, while the overall antibody structure and Fc region are optimized to modulate immune activation. This allows selective targeting of malignant cells with high affinity while using the Fc region to control the degree and type of immune response, reducing off-target harm.
3Reliability
If chimeric and humanized antibodies are designed to target CD22, then specificity is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody into distinct functional modules: variable regions (with engineered CDR1, CDR2, CDR3 for antigen binding) and constant regions (for immune effector functions). The chimeric and humanized designs segment the variable regions from different species while maintaining human constant regions, allowing independent optimization of binding affinity and immunogenicity characteristics.
Solution Approach 2:
The patent uses intermediary structures by introducing human framework regions as intermediaries between murine CDR sequences and human constant regions. This humanized framework acts as a mediator that maintains the conformation and function of the non-human CDRs while reducing immunogenicity and improving pharmacokinetic properties, thereby simplifying manufacturing and clinical development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies provide high specificity and affinity for CD22, enabling effective targeting and monitoring of CD22-expressing cells, potentially leading to improved therapeutic outcomes and diagnostic precision.
Implementation Method 1
CD22, a lineage-restricted B cell antigen that belongs to the Ig superfamily, is expressed on the surface of many types of malignant B cells
Implementation Method 2
which can induce apoptosis in CD22-expressing cells
Data Source
AI summary
The present disclosure provides antibodies specific for an epitope present on CD22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.